Literature DB >> 8160599

Legal and ethical aspects of driving and working in patients with an implantable cardioverter defibrillator.

M H Anderson1, A J Camm.   

Abstract

Automobile driving is essential to work and leisure for many people, and patients with implantable cardioverter defibrillators (ICDs) are no exception. Whether patients who may suffer sudden incapacitation should be allowed to drive raises important ethical and legal issues. The opinion of physicians regarding when or if it is safe to drive with an ICD varies, and most countries have no regulations to assist such decisions. Such regulations can best be developed by actuarial analysis of the risks involved, although the limited volume of published data on the ICD hinders this process. A policy based on very low levels of social risk from driving by patients with ICDs or a comparison with epileptic patients suggests a ban on driving for 12 to 24 months after ICD implantation. Patients who have received therapy from the ICD within this period would not be granted a driver's licence. As further data from actuarial studies become available, these guidelines could be relaxed for patients at low risk of therapy delivery.

Entities:  

Keywords:  Empirical Approach; Health Care and Public Health; Legal Approach; Professional Patient Relationship

Mesh:

Year:  1994        PMID: 8160599     DOI: 10.1016/0002-8703(94)90108-2

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  3 in total

1.  Driving and arrhythmias.

Authors:  Helen Binns; John Camm
Journal:  BMJ       Date:  2002-04-20

2.  Should patients with implantable cardioverter-defibrillators be allowed to drive? Observations in 291 patients from a single center over an 11-year period.

Authors:  H J Trappe; P Wenzlaff; G Grellman
Journal:  J Interv Card Electrophysiol       Date:  1998-06       Impact factor: 1.900

3.  Driving restrictions after implantable cardioverter defibrillator implantation: an evidence-based approach.

Authors:  Joep Thijssen; C Jan Willem Borleffs; Johannes B van Rees; Mihály K de Bie; Enno T van der Velde; Lieselot van Erven; Jeroen J Bax; Suzanne C Cannegieter; Martin J Schalij
Journal:  Eur Heart J       Date:  2011-06-05       Impact factor: 29.983

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.